2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses the toxicities associated with belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, consultant hematologist, University College Hospital, honorary associate professor, University College London, discusses the toxicities associated with belantamab mafodotin-blmf (Blenrep) in relapsed/refractory multiple myeloma.
Weighing the risks and benefits of all therapies in oncology is an important step of the treatment-decision process, Popat says. Moreover, all treatment recommendations should be personalized to the individual patient.
Findings from the phase 2 DREAMM-2 trial (NCT03525678), which led to the August 2020 FDA approval of belantamab mafodotin, demonstrated clinical activity and a tolerable safety profile with the antibody-drug conjugate in patients with heavily pretreated relapsed/refractory multiple myeloma. Notably, most patients who required treatment discontinuations stopped treatment because of disease progression rather than adverse effects (AEs), Popat says.
Regardless, making a patient aware of the potential toxicities associated with belantamab mafodotin, including thrombocytopenia and keratopathy, is critical, Popat explains. Moreover, explaining how these AEs could affect a patient’s quality of life, as well as the how the efficacy of the agent compares with that of standard of care therapies, is important, Popat concludes.
Related Content: